CDK4 and Decreased total leukocyte count: Line of treatment seemed to be important for the occurrence of adverse events as patients treated in first line with CDK4/6 had less leukopenia (p = 0.03), but not any of the other adverse events (all p > 0.05) compared to patients treated in second line or beyond.